News

As part of this agreement, Boehringer Ingelheim will utilise IQVIA’s data-as-a-service (DaaS+) technology to advance its global commercial data transformation, aiming to streamline data management and analytics across

The partnership will focus on creating treatments intended to restore immune homeostasis and deliver durable remission for patients, avoiding the generalised immune suppression associated with existing therapies. Under

The financing includes a €20m strategic investment from Sanofi and €40m from existing and new investors such as Artal (advised by Invus), Redmile Group, Cormorant Asset Management, Sofinnova

This designation aims to expedite the development and review of medicines for serious conditions. The FDA based its decision on comprehensive data, including findings from the Phase II

Otsuka’s NDA covers the use of centanafadine as a treatment for ADHD in adolescents, adults, and children. Centanafadine is a norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI). The

The partnership will leverage Insilico’s Pharma.AI platform for the development of small molecule inhibitors, with the agreement valued at nearly $120m. This agreement includes development and commercial milestone

Agreed in December 2025, the transaction is valued at up to $820m and brings the late-stage monoclonal antibody brelovitug, a candidate for chronic hepatitis delta virus (HDV), into

The submission relates to patients with mild cognitive impairment or mild dementia due to Alzheimer’s. The FDA has set a Prescription Drug User Fee Act (PDUFA) action date

For the entire year, sales grew by 6% to $94.2bn, and full-year earnings per share (EPS) registered at $11.03. The diluted earnings per share (EPS) for Q4 2025